317 related articles for article (PubMed ID: 19667989)
41. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
42. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE
Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
[TBL] [Abstract][Full Text] [Related]
43. Role of proteasome inhibition in sensitized transplant candidates.
Everly MJ; Everly JJ; Terasaki PI
Chin Med J (Engl); 2011 Mar; 124(5):771-4. PubMed ID: 21518574
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib: a new player in pre- and post-transplant desensitization?
Lemy A; Toungouz M; Abramowicz D
Nephrol Dial Transplant; 2010 Nov; 25(11):3480-9. PubMed ID: 20826741
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
46. Antibody-mediated rejection in kidney transplantation: an update.
Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
[TBL] [Abstract][Full Text] [Related]
47. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD
Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
[No Abstract] [Full Text] [Related]
49. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Gomez AM; Willcox N; Molenaar PC; Buurman W; Martinez-Martinez P; De Baets MH; Losen M
Ann N Y Acad Sci; 2012 Dec; 1274():48-59. PubMed ID: 23252897
[TBL] [Abstract][Full Text] [Related]
50. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
51. Proteasome inhibition: a new therapeutic option in lupus nephritis?
van der Vlag J; Berden JH
Nephrol Dial Transplant; 2008 Dec; 23(12):3771-2. PubMed ID: 18809973
[No Abstract] [Full Text] [Related]
52. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
[TBL] [Abstract][Full Text] [Related]
53. [Proteasome inhibitors--new option in the treatment of tumor diseases].
Spicka I; Klener P
Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
[TBL] [Abstract][Full Text] [Related]
54. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
55. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
56. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
57. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
[TBL] [Abstract][Full Text] [Related]
59. Proteasome inhibitors: poisons and remedies.
Meiners S; Ludwig A; Stangl V; Stangl K
Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
[TBL] [Abstract][Full Text] [Related]
60. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
Gerlach UA; Schoenemann C; Lachmann N; Koch M; Pascher A
Transpl Int; 2011 May; 24(5):e43-5. PubMed ID: 21155900
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
